| 1 |
34894066 | Clinical and molecular response to dasatinib in an adult patient with Penttinen syndrome. | 2022 Apr |
2 |
| 2 |
34203261 | Imatinib (STI571) Inhibits the Expression of Angiotensin-Converting Enzyme 2 and Cell Entry of the SARS-CoV-2-Derived Pseudotyped Viral Particles. | 2021 Jun 28 |
1 |
| 3 |
34944663 | Selective Inhibition of HDAC Class I Sensitizes Leukemia and Neuroblastoma Cells to Anticancer Drugs. | 2021 Dec 6 |
1 |
| 4 |
33066449 | Therapeutic Potential of PI3K/AKT/mTOR Pathway in Gastrointestinal Stromal Tumors: Rationale and Progress. | 2020 Oct 14 |
1 |
| 5 |
29697413 | Inhibition of fibroblast growth factor receptor-signaling sensitizes imatinib-resistant gastrointestinal stromal tumors to low doses of topoisomerase II inhibitors. | 2018 Jul |
2 |
| 6 |
28768491 | Succinate dehydrogenase deficiency in a PDGFRA mutated GIST. | 2017 Aug 2 |
2 |
| 7 |
28915580 | Molecular and functional characterization of a new 3' end KIT juxtamembrane deletion in a duodenal GIST treated with neoadjuvant Imatinib. | 2017 Aug 22 |
1 |
| 8 |
26026391 | KIT Signaling Promotes Growth of Colon Xenograft Tumors in Mice and Is Up-Regulated in a Subset of Human Colon Cancers. | 2015 Sep |
1 |
| 9 |
26098203 | Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor. | 2015 |
2 |
| 10 |
30349606 | Current and Future Perspectives in Thyroid Carcinoma Treatment. | 2013 Mar |
1 |
| 11 |
22286373 | RET TKI: potential role in thyroid cancers. | 2012 Apr |
1 |
| 12 |
19900123 | Targeted therapies in the treatment of GIST: Adverse events and maximising the benefits of sunitinib through proactive therapy management. | 2010 |
4 |
| 13 |
18314611 | [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors]. | 2007 |
1 |
| 14 |
16401709 | Management of gastrointestinal stromal tumors in the imatinib era: selected case studies. | 2006 Jan |
1 |
| 15 |
16782438 | Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations. | 2006 Jun |
5 |
| 16 |
17064855 | Gastrointestinal stromal tumors: a contemporary review. | 2006 |
2 |
| 17 |
15709206 | Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. | 2005 Feb 1 |
1 |
| 18 |
15922853 | c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. | 2005 Jul 8 |
2 |
| 19 |
15548358 | Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors. | 2004 Sep-Oct |
2 |
| 20 |
14666655 | RET tyrosine kinase and medullary thyroid cells are unaffected by clinical doses of STI571. | 2003 Sep-Oct |
3 |
| 21 |
12490842 | Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. | 2002 Dec |
1 |